Business Description
Avenue Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US05360L3042
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.96 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 40.8 | |||||
3-Year EPS without NRI Growth Rate | 33.3 | |||||
3-Year FCF Growth Rate | 38.2 | |||||
3-Year Book Growth Rate | -69.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 68.5 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.29 | |||||
9-Day RSI | 48.33 | |||||
14-Day RSI | 44.61 | |||||
6-1 Month Momentum % | -75.28 | |||||
12-1 Month Momentum % | -94.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.3 | |||||
Quick Ratio | 4.3 | |||||
Cash Ratio | 4.24 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -184.1 | |||||
Shareholder Yield % | -156.26 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -26428.57 | |||||
ROA % | -420.59 | |||||
ROIC % | -492.15 | |||||
3-Year ROIIC % | -1624.91 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.53 | |||||
Price-to-Tangible-Book | 0.56 | |||||
EV-to-EBIT | 0.32 | |||||
EV-to-Forward-EBIT | -0.36 | |||||
EV-to-EBITDA | 0.32 | |||||
EV-to-FCF | 0.22 | |||||
Price-to-Net-Current-Asset-Value | 0.56 | |||||
Price-to-Net-Cash | 0.56 | |||||
Earnings Yield (Greenblatt) % | 309.68 | |||||
FCF Yield % | -285.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Avenue Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -14.204 | ||
Beta | 0 | ||
Volatility % | 72.59 | ||
14-Day RSI | 44.61 | ||
14-Day ATR (€) | 0.073699 | ||
20-Day SMA (€) | 1.946 | ||
12-1 Month Momentum % | -94.78 | ||
52-Week Range (€) | 1.77 - 34.53 | ||
Shares Outstanding (Mil) | 1.43 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Avenue Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Avenue Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Avenue Therapeutics Inc Frequently Asked Questions
What is Avenue Therapeutics Inc(FRA:49Y)'s stock price today?
When is next earnings date of Avenue Therapeutics Inc(FRA:49Y)?
Does Avenue Therapeutics Inc(FRA:49Y) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |